Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Research & Development (2018 - 2025)

IGC Pharma (IGC) has disclosed Research & Development for 8 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 73.17% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a 20.31% increase, with the full-year FY2025 number at $3.7 million, down 3.13% from a year prior.
  • Research & Development was $1.6 million for Q3 2025 at IGC Pharma, up from $851000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.6 million in Q3 2025 to a low of $276000.0 in Q3 2021.
  • A 5-year average of $840631.6 and a median of $852000.0 in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 294.43% in 2022, then tumbled 55.78% in 2023.
  • IGC Pharma's Research & Development stood at $377000.0 in 2021, then surged by 113.79% to $806000.0 in 2022, then rose by 12.03% to $903000.0 in 2023, then decreased by 5.65% to $852000.0 in 2024, then skyrocketed by 86.38% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Research & Development are $1.6 million (Q3 2025), $851000.0 (Q2 2025), and $997000.0 (Q1 2025).